Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.
about
Early failure of the default-mode network and the pathogenesis of Alzheimer's diseaseNanoparticle-based monitoring of cell therapy.Functional neuroimaging in Parkinson's diseaseNeuroimaging of Parkinson's disease: Expanding views.Foundations of advanced magnetic resonance imaging.Neuroimaging of ischemia and infarction.Imaging of multiple sclerosis: role in neurotherapeutics.Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease.Neuroimaging and therapeutics in movement disorders.Single-photon emission computed tomography in neurotherapeuticsMagnetic resonance imaging, microscopy, and spectroscopy of the central nervous system in experimental animals.Recent progress of imaging agents for Parkinson's disease.Molecular optical imaging: applications leading to the development of present day therapeuticsNeuroimaging of epilepsy: therapeutic implications.Enhanced selective serotonin re-uptake inhibitors as antidepressants: 2004 - 2006.A review of imaging methods for measuring drug release at nanometre scale: a case for drug delivery systems.Neuroimaging: anything to do with neurotherapeutics?Exploring new routes for neuroprotective drug development in traumatic brain injury.Support vector machine-based classification of neuroimages in Alzheimer's disease: direct comparison of FDG-PET, rCBF-SPECT and MRI data acquired from the same individuals.Preparation and biological evaluation of (99m)Tc-ropinirole as a novel radiopharmaceutical for brain imaging.Novel radiochemical and biological characterization of 99mTc-histamine as a model for brain imaging
P2860
Q26862463-D1A9DE26-CE78-4B66-AF6C-88B6EE4759E9Q27000646-77ED0734-C032-499F-B978-453B00D4877EQ27013767-91669A7A-D6C1-4F4D-BA47-400F768F9516Q28387732-721AF849-637C-42F6-ABA2-5896D77939FDQ30499144-0D7D17D4-444D-4613-8705-8864A74F20E0Q30989931-EB123A64-4087-42AD-8434-A8FCD91FEF12Q30989935-A6F18B20-B006-4E2E-B816-867F0C477B08Q30989943-9FCD4A1E-A3A1-4165-95EE-23AFAD950FD7Q30989947-A9526405-1B07-492A-8EC7-80EDBD5B064FQ33716200-A6D9F872-630A-4B2F-9F0F-5BD703E5C456Q33716206-813B1C5B-7F32-4DEE-BBFD-C51F0CFB7405Q35595426-DA39B716-50CB-41FA-99DC-D4FE3886A034Q36129726-EBABDABA-EEF3-40EA-83FB-A837D51A978EQ36129741-3DBE165A-2EE3-4C29-BFBA-919DC70BA24DQ37689787-0483530F-3E99-45E2-ACFB-09C8A40D8633Q37974934-99D0E272-85C8-4954-89E2-EB6665121521Q42704917-006E5043-2031-4813-B7AC-988100307F08Q46152263-C2EC5139-836B-44A5-84F2-0BDE3C3A5C78Q47184005-61DD23A1-7C89-46FB-A9AC-C4CF2ED6B796Q48879813-B14CE671-CC1E-42EB-A83C-2BD9A46A2F61Q59322220-3BDC8673-950A-4B87-9038-4897FCA850BE
P2860
Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Positron emission tomography a ...... rvous system drug development.
@ast
Positron emission tomography a ...... rvous system drug development.
@en
type
label
Positron emission tomography a ...... rvous system drug development.
@ast
Positron emission tomography a ...... rvous system drug development.
@en
prefLabel
Positron emission tomography a ...... rvous system drug development.
@ast
Positron emission tomography a ...... rvous system drug development.
@en
P2860
P356
P1433
P1476
Positron emission tomography a ...... ervous system drug development
@en
P2093
David J Brooks
P2860
P304
P356
10.1602/NEURORX.2.2.226
P577
2005-04-01T00:00:00Z